Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Brenner

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
American Journal of Alzheimer'S Disease and Other Dementias|June 19, 2010
Cognitive status changes based on time of day in nursing home patients with and without dementiaSubramoniam Madhusoodanan, Neha Madhusoodanan, Mark Serper, et al.
Psychiatry (Edgmont (Pa. : Township))|October 22, 2010
Psychological symptoms in paid caregivers of dementia patients: a pilot studyRonald Brenner, Subramoniam Madhusoodanan, Ella Brodsky, et al.
Schizophrenia Research|November 18, 2011
Assessment of the effects of AZD3480 on cognitive function in patients with schizophreniaDawn Velligan, Ronald Brenner, Franco Sicuro, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|November 16, 2005
Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trialPierre N Tariot, Rema Raman, Laura Jakimovich, et al.
Schizophrenia Bulletin|May 3, 2018
Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II TrialDavid Brown, Kazuyuki Nakagome, Joachim Cordes, et al.
BMC Psychiatry|December 26, 2014
A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophreniaAnnCatherine M Downing, Bruce J Kinon, Brian A Millen, et al.
The Lancet. Psychiatry|February 21, 2021
Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 studyW Wolfgang Fleischhacker, Jana Podhorna, Martina Gröschl, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
American Journal of Alzheimer'S Disease and Other Dementias|June 19, 2010
Cognitive status changes based on time of day in nursing home patients with and without dementiaSubramoniam Madhusoodanan, Neha Madhusoodanan, Mark Serper, et al.
Psychiatry (Edgmont (Pa. : Township))|October 22, 2010
Psychological symptoms in paid caregivers of dementia patients: a pilot studyRonald Brenner, Subramoniam Madhusoodanan, Ella Brodsky, et al.
Schizophrenia Research|November 18, 2011
Assessment of the effects of AZD3480 on cognitive function in patients with schizophreniaDawn Velligan, Ronald Brenner, Franco Sicuro, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|November 16, 2005
Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trialPierre N Tariot, Rema Raman, Laura Jakimovich, et al.
Schizophrenia Bulletin|May 3, 2018
Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II TrialDavid Brown, Kazuyuki Nakagome, Joachim Cordes, et al.
BMC Psychiatry|December 26, 2014
A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophreniaAnnCatherine M Downing, Bruce J Kinon, Brian A Millen, et al.
The Lancet. Psychiatry|February 21, 2021
Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 studyW Wolfgang Fleischhacker, Jana Podhorna, Martina Gröschl, et al.
Pageof 3